PMID- 3292596
OWN - NLM
STAT- MEDLINE
DCOM- 19880823
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 28
IP  - 4
DP  - 1988 Apr
TI  - Epoprostenol (prostacyclin) in unstable angina.
PG  - 300-5
AB  - The purpose of this randomized, double-blind multicenter trial was to investigate 
      the potential therapeutic effect of epoprostenol (prostacyclin, PGI2) in patients 
      with unstable angina, as compared with placebo, and to investigate the safety of 
      this agent. Of the 184 patients enrolled, 28 did not fit the study criteria; of 
      the remaining 156 patients, 30 received prostacyclin in an open-label fashion. In 
      the double-blind portion of the study, 63 patients each received prostacyclin or 
      placebo. The drug or its vehicle was infused intravenously up to 5 ng/kg/min dose 
      for 72 hours with a tapering off period for the last 12 hours. Both treatment 
      groups from the double-blind portion were comparable in regard to the demographic 
      data, length of infusion, and total dose received. There were no significant 
      differences between the placebo and prostacyclin group in the following clinical 
      endpoints: levels of cardiac enzymes throughout hospitalization period (with the 
      exception of lower SGOT level in the prostacyclin group at day 2), and severity 
      of angina (throughout the study), and at the end of the study (day 30). The 
      number of patients who had congestive heart failure, new myocardial infarction, 
      balloon pump insertion, coronary artery bypass grafting, or percutaneous coronary 
      angioplasty was similar in both groups. Similar results in regard to the efficacy 
      endpoints were also apparent in the prostacyclin group that was treated under 
      open-label fashion. There was also no difference in the New York Heart 
      Association (NYHA) functional status at the end of the double-blind 
      study.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Lichstein, E
AU  - Lichstein E
AD  - Maimonides Medical Center, Brooklyn, New York.
FAU - Mendizabal, R
AU  - Mendizabal R
FAU - Theroux, P
AU  - Theroux P
FAU - Muller, O
AU  - Muller O
FAU - Willerson, J T
AU  - Willerson JT
FAU - Rapaport, E
AU  - Rapaport E
FAU - Molk, B L
AU  - Molk BL
FAU - Linet, O I
AU  - Linet OI
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/*drug therapy
MH  - Angina, Unstable/*drug therapy
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Epoprostenol/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1988.tb03147.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1988 Apr;28(4):300-5. doi: 10.1002/j.1552-4604.1988.tb03147.x.